Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vaxart Inc VXRT

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its... see more

Recent & Breaking News (NDAQ:VXRT)

VXRT SHAREHOLDER INVESTIGATION: Bernstein Liebhard Announces an Investigation into Vaxart, Inc., and Encourages Investors to Contact the Firm

PR Newswire July 27, 2020

SHAREHOLDER ALERT: Schubert Firm Investigating Possible Legal Claims on Behalf of Vaxart, Inc. Shareholders

PR Newswire July 27, 2020

Norovirus Gastroenteritis Costs an Estimated $10.6 Billion Each Year in the United States

GlobeNewswire July 16, 2020

Vaxart Raises Approximately $90M in Gross Proceeds Through its At-The-Market-Facility

GlobeNewswire July 13, 2020

Vaxart's COVID-19 Vaccine Selected for the U.S. Government's Operation Warp Speed

GlobeNewswire June 26, 2020

Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP

GlobeNewswire June 25, 2020

Vaxart, Inc. Set to Join Russell 3000® Index

GlobeNewswire June 24, 2020

Vaxart, Inc. to Present at the H.C. Wainwright Virtual Fireside Chat Series

GlobeNewswire June 23, 2020

Vaxart, Inc. Appoints New CEO to Accelerate Advancement of COVID-19 and Other Programs

GlobeNewswire June 15, 2020

Vaxart to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire June 3, 2020

Vaxart Announces Selection of its Oral COVID-19 Vaccine Lead Candidate

GlobeNewswire May 20, 2020

Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart

PR Newswire May 20, 2020

Vaxart Announces First Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire May 12, 2020

Vaxart Announces Additional Positive Pre-Clinical Data for its Oral COVID-19 Vaccine Program

GlobeNewswire April 30, 2020

Vaxart Announces Corporate Update for First Quarter 2020

GlobeNewswire April 28, 2020

INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Vaxart, Inc. for Potential Breach of Fiduciary Duty Claims

GlobeNewswire April 27, 2020

Vaxart Announces Positive Pre-Clinical Data for its Oral COVID-19 Vaccine Program

GlobeNewswire April 21, 2020

Vaxart Provides Update on its Oral COVID-19 Vaccine Program

GlobeNewswire March 31, 2020

Identifying the Significant Differences Among Head-Start Candidates in Race for Coronavirus Vaccine

Livemoney March 25, 2020

Vaxart Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

GlobeNewswire March 19, 2020